nuvisertib [Ligand Id: 13215] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL3975308 (Nuvisertib, SGI-9481, SGI9481, Tp-3654, TP-3654, TP3654) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| Pim-1 proto-oncogene, serine/threonine kinase/Serine/threonine-protein kinase pim-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2147] [GtoPdb: 2158] [UniProtKB: P11309] | ||||||||
| GtoPdb | - | - | 8.3 | pKi | 5 | nM | Ki | Neoplasia (2014) 16: 403-12 [PMID:24953177] |
| ChEMBL | Inhibition of PIM1 (unknown origin) up to 120 mins by Michaelis-Menten plot analysis | B | 8.3 | pKi | 5 | nM | Ki | Eur J Med Chem (2019) 172: 95-108 [PMID:30954777] |
| ChEMBL | Inhibition of PIM1 (unknown origin) | B | 8.3 | pIC50 | 5 | nM | IC50 | J Med Chem (2024) 67: 38-64 [PMID:38164076] |
| ChEMBL | Kinase-Glo Assay: These assays are set up in duplicate 50 ul volumes in white, flat bottom 96 well plates. Inhibitors are added to the solution of 1Ă— kinase buffer, 10 uM ATP, 100 uM Pim-1-specific substrate, 50 ng of active Pim-1 enzyme, and water in serial dilutions ranging from micromolar to nanomolar concentrations. This solution is incubated at 30 degrees Celsius at 360 rpm for two hours. Following the incubation, 50 ul of Kinase-Glo reagent is added to each well, including all positive and negative control wells, and incubated at room temperature for 15 minutes. The plate is then read by the Luminoskan Ascent instrument and the results displayed with the Ascent Software version 2.6. | B | 9 | pIC50 | 1 | nM | IC50 | US-9416132-B2. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors (2016) |
| ChEMBL | Kinase-Glo Assay: These assays are set up in duplicate 50 ul volumes in white, flat bottom 96 well plates. Inhibitors are added to the solution of 1Ă— kinase buffer, 10 uM ATP, 100 uM Pim-1-specific substrate, 50 ng of active Pim-1 enzyme, and water in serial dilutions ranging from micromolar to nanomolar concentrations. This solution is incubated at 30 degrees Celsius at 360 rpm for two hours. Following the incubation, 50 ul of Kinase-Glo reagent is added to each well, including all positive and negative control wells, and incubated at room temperature for 15 minutes. The plate is then read by the Luminoskan Ascent instrument and the results displayed with the Ascent Software version 2.6. | B | 9 | pIC50 | 1 | nM | IC50 | US-9416132-B2. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors (2016) |
| ChEMBL | Pim-1 Kinase Inhibition Assay: One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro Pim-1 kinase reaction. The Kinase-Glo Assay Kit (Promega, Inc., Madison, Wis.) allows this. The amount of ATP remaining in the solution after the kinase reaction serves as a substrate for the luciferase to catalyze luciferin to oxyluciferin plus one photon of light. Thus, the luminescent signal read by the Luminoskan Ascent Instrument (Thermo Electron Corp., Milford, Mass.) correlates with the amount of ATP present after the kinase reaction and inversely correlates with the amount of kinase activity. This assay is efficient at determining the IC50 values of kinase inhibitors against the Pim-1 kinase. These assays are set up in duplicate 50 ul volumes in white, flat bottom 96 well plates. Inhibitors are added to the solution of 1Ă— kinase buffer, 10 uM ATP, 100 uM Pim-1-specific substrate, 50 ng of active Pim-1 enzyme, and water in serial dilutions ranging from micromolar to nanomolar concentrations. This solution is incubated at 30 degrees Celsius at 360 rpm for two hours. Following the incubation, 50 ul of Kinase-Glo reagent is added to each well, including all positive and negative control wells, and incubated at room temperature for 15 minutes. The plate is then read by the Luminoskan Ascent instrument and the results displayed with the Ascent Software version 2.6. The IC50 values can then be calculated for each inhibitor tested. | B | 9 | pIC50 | 1 | nM | IC50 | US-10047093-B2. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2018) |
| ChEMBL | Kinase Inhibition Assay: One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro Pim-1 kinase reaction. The Kinase-Glo Assay Kit (Promega, Inc., Madison, Wis.) allows this. The amount of ATP remaining in the solution after the kinase reaction serves as a substrate for the luciferase to catalyze luciferin to oxyluciferin plus one photon of light. Thus, the luminescent signal read by the Luminoskan Ascent Instrument (Thermo Electron Corp., Milford, Mass.) correlates with the amount of ATP present after the kinase reaction and inversely correlates with the amount of kinase activity. This assay is efficient at determining the IC50 values of kinase inhibitors against the Pim-1 kinase. These assays are set up in duplicate 50 ul volumes in white, flat bottom 96 well plates. Inhibitors are added to the solution of 1Ă— kinase buffer, 10 uM ATP, 100 uM Pim-1-specific substrate, 50 ng of active Pim-1 enzyme, and water in serial dilutions ranging from micromolar to nanomolar concentrations. This solution is incubated at 30 degrees Celsius at 360 rpm for two hours. Following the incubation, 50 ul of Kinase-Glo reagent is added to each well, including all positive and negative control wells, and incubated at room temperature for 15 minutes. The plate is then read by the Luminoskan Ascent instrument and the results displayed with the Ascent Software version 2.6. The IC50 values can then be calculated for each inhibitor tested. | B | 9 | pIC50 | 1 | nM | IC50 | US-10392392-B2. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2019) |
| ChEMBL | Pim-1 Kinase Inhibition Assay: One illustrative manner in which Pim-1 kinase activity can be determined is by quantifying the amount of ATP remaining in solution after an in vitro Pim-1 kinase reaction. The Kinase-Glo Assay Kit (Promega, Inc., Madison, Wis.) allows this. The amount of ATP remaining in the solution after the kinase reaction serves as a substrate for the luciferase to catalyze luciferin to oxyluciferin plus one photon of light. Thus, the luminescent signal read by the Luminoskan Ascent Instrument (Thermo Electron Corp., Milford, Mass.) correlates with the amount of ATP present after the kinase reaction and inversely correlates with the amount of kinase activity. This assay is efficient at determining the IC50 values of kinase inhibitors against the Pim-1 kinase. These assays are set up in duplicate 50 ul volumes in white, flat bottom 96 well plates. Inhibitors are added to the solution of 1Ă— kinase buffer, 10 uM ATP, 100 uM Pim-1-specific substrate, 50 ng of active Pim-1 enzyme, and water in serial dilutions ranging from micromolar to nanomolar concentrations. This solution is incubated at 30 degrees Celsius at 360 rpm for two hours. Following the incubation, 50 ul of Kinase-Glo reagent is added to each well, including all positive and negative control wells, and incubated at room temperature for 15 minutes. The plate is then read by the Luminoskan Ascent instrument and the results displayed with the Ascent Software version 2.6. The IC50 values can then be calculated for each inhibitor tested. For Ki determination, PIM-1 were incubated with 10-dose, 3-fold serial dilutions of compound starting with 10 ÎĽM using 5 different concentrations of ATP (25, 50, 100, 250 and 500 ÎĽM ATP for PIM-1; 5, 10, 20, 50 and 100 ÎĽM ATP for PIM-2 and PIM-3), and the activity was measured at 0, 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes. The data was analyzed in a Michaelis-Menton plot to determine apparent Km and Ki values using GraFit software using a mixed inhibition equation for global fit. | B | 9 | pIC50 | 1 | nM | IC50 | US-10875864-B2. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2020) |
| Pim-2 proto-oncogene, serine/threonine kinase/Serine/threonine-protein kinase pim-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523] [GtoPdb: 2159] [UniProtKB: Q9P1W9] | ||||||||
| GtoPdb | - | - | 6.62 | pKi | 239 | nM | Ki | Neoplasia (2014) 16: 403-12 [PMID:24953177] |
| ChEMBL | Inhibition of PIM2 (unknown origin) | B | 6.62 | pIC50 | 239 | nM | IC50 | J Med Chem (2024) 67: 38-64 [PMID:38164076] |
| Pim-3 proto-oncogene, serine/threonine kinase/Serine/threonine-protein kinase pim-3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5407] [GtoPdb: 2160] [UniProtKB: Q86V86] | ||||||||
| GtoPdb | - | - | 7.38 | pKi | 42 | nM | Ki | Neoplasia (2014) 16: 403-12 [PMID:24953177] |
| ChEMBL | Inhibition of PIM3 (unknown origin) | B | 7.38 | pIC50 | 42 | nM | IC50 | J Med Chem (2024) 67: 38-64 [PMID:38164076] |
| Kv11.1/Voltage-gated inwardly rectifying potassium channel KCNH2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] | ||||||||
| ChEMBL | Fast Patch Assay: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China). | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-9416132-B2. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors (2016) |
| ChEMBL | hERG Activity Assays: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China). | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-10047093-B2. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2018) |
| ChEMBL | Activity Assay: hERG activity assays representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China). | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-10392392-B2. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2019) |
| ChEMBL | hERG Activity Assays: Representative compounds were tested for hERG activity using the Fast Patch assay available from WuXiApptec (Shanghai China). | B | 4.52 | pIC50 | >30000 | nM | IC50 | US-10875864-B2. Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors (2020) |
| fms related receptor tyrosine kinase 3 in Human [GtoPdb: 1807] [UniProtKB: P36888] | ||||||||
| GtoPdb | - | - | 6.55 | pIC50 | 279 | nM | IC50 | Neoplasia (2014) 16: 403-12 [PMID:24953177] |
ChEMBL data shown on this page come from version 36:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
